XXXX -based treatment in @entity730 : a consecutive case series.

@entity1 @entity730 @entity15451 @entity158 @entity454
BACKGROUND: @entity730 ( @entity730 ) is a rare complication in @entity454 with high mortality. Numerous case reports and one case series of 3 @entity1 report the benefit of @entity15451 (STS) for treatment of @entity730 . The purpose of this evaluation was to examine the response to a STS-based treatment approach in @entity1 with @entity730 with 1 year follow up. METHODS: A retrospective case series of 6 consecutive @entity1 from Manitoba, Canada who met predefined diagnostic criteria for @entity730 and received STS between 2006 and 2008 were included. STS responders were defined as improvement in at least one of the following three parameters: @entity158 severity, wound size and diagnostic imaging/radiography. Mortality, STS dose, duration, adverse events and cost were also collected. RESULTS: Four @entity1 were classified as responders. The 2 responders who survived at 1 year of follow-up demonstrated an improvement in all 3 parameters examined including an improvement in their follow-up diagnostic imaging results within the first 4 - 6 weeks of STS treatment. At 1 year of follow-up, 3 @entity1 died. CONCLUSION: Using an STS-based multifaceted treatment approach for @entity730 , 4 @entity1 responded but 3 of 6 @entity1 died within 1 year. Further larger prospective studies are needed to delineate STS responders from non-responders.
